At what enterprise value was HUBLO acquired in 2025?

During the acquisition of HUBLO by FIVE ARROWS in 2025, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of HUBLO when it was acquired by FIVE ARROWS?

The exact EV/EBITDA multiple for HUBLO is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was HUBLO acquired by FIVE ARROWS?

HUBLO was acquired by FIVE ARROWS in 2025.

What was the revenue of HUBLO at the time of the deal?

The revenue of HUBLO at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the HUBLO acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the HUBLO deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/five-arrows-arrive-chez-hublo-2172178

← DATABASE

Home Database Healthcare & PharmaHUBLO

05/2025

HUBLO acquired by FIVE ARROWS

FRANCE Healthcare Services / Health Tech EV 100M - 350M EUR

Context

Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe. The partnership will focus on product innovation (AI integration for planning) and potential strategic acquisitions to build a comprehensive HR platform for the healthcare sector.

HUBLO, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

A leading European digital platform for healthcare workforce management. Hublo helps hospitals, nursing homes, and clinics manage their internal and external staff replacements efficiently. By automating the recruitment and mobilization process of temporary workers and internal pools, it addresses the critical shortage of healthcare professionals. It serves over 3,500 facilities and 800,000 healthcare professionals in Europe (France and Germany).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
11/2025	ASKER HEALTHCARE GROUP	FINMED GROUP	FRANCE	Healthcare Services	Asker Healthcare Group has signed a definitive agreement to acquire 80% of the shares in Finmed Group, marking its strategic entry into the French healthcare market. This transaction serves as a platform acquisition, providing the Swedish-based group with a robust foundation to expand its presence in one of Europe's largest medical device markets
10/2025	EVOLEM	APPERTON	FRANCE	Healthcare Services	A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates
04/2025	TRANSCARENT	ACCOLADE	UNITED STATES	Healthcare Services	Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group
04/2025	KERSIA	NEOGEN (ANIMAL BIOSECURITY DIVISION)	UNITED STATES	Healthcare Services	Kersia is acquiring the animal biosecurity cleaners and disinfectants business from Neogen® through an exclusive agreement. This strategic transaction marks a major entry for the French group into the North American swine and poultry markets, complementing its existing domestic presence in the ruminant sector
07/2024	ARDIAN	MASCO GROUP	ITALY	Healthcare Services	Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering
06/2024	PERMIRA	PHARMACORD	UNITED STATES	Healthcare Services	PharmaCord has been acquired by a company backed by Permira following a definitive agreement signed in June 2024. The transaction introduces new capital to PharmaCord while the existing management team, led by founder and CEO Nitin Sahney, retains operational control and a significant equity position
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services	21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	Healthcare Services	Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	Healthcare Services	Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	Healthcare Services	Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HUBLO by FIVE ARROWS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: hublo

Acquirer: five arrows